X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-05 | NBIX | Neurocrine Biosciences Inc | Rastetter William H | Dir | S - Sale+OE | $151.82 | -18,000 | 40,360 | -31% | -$2,732,690 | |||||
| D | 2025-11-04 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $5.21 | -40,000 | 954,229 | -4% | -$208,400 | |||||
2025-11-05 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $8.10 | -10,000 | 82,318 | -11% | -$81,000 | ||||||
2025-11-03 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $32.08 | -1,019 | 120,694 | -1% | -$32,689 | ||||||
2025-11-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $32.08 | -2,755 | 265,919 | -1% | -$88,379 | ||||||
2025-11-03 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $32.08 | -1,084 | 142,187 | -1% | -$34,774 | ||||||
| D | 2025-11-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $32.08 | -4,887 | 733,922 | -1% | -$156,772 | |||||
2025-11-03 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $32.08 | -160 | 50,870 | 0% | -$5,133 | ||||||
2025-11-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.59 | -292 | 405,131 | 0% | -$171 | ||||||
| D | 2025-11-04 | NBIX | Neurocrine Biosciences Inc | Gano Kyle | CEO | S - Sale+OE | $141.97 | -300 | 140,407 | 0% | -$42,591 | |||||
2025-11-03 | VIR | Vir Biotechnology, Inc. | De Verneuil Vanina | EVP, GC | S - Sale | $5.86 | -1,365 | 80,595 | -2% | -$8,003 | ||||||
| D | 2025-11-03 | DTIL | Precision Biosciences Inc | Kelly John Alexander | CFO | S - Sale+OE | $6.49 | -1,303 | 77,298 | -2% | -$8,456 | |||||
| D | 2025-11-03 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC, Secretary | S - Sale+OE | $6.49 | -665 | 28,258 | -2% | -$4,316 | |||||
| D | 2025-11-03 | DTIL | Precision Biosciences Inc | Amoroso Michael | Pres, CEO | S - Sale+OE | $6.49 | -3,409 | 115,575 | -3% | -$22,124 | |||||
2025-11-03 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $7.00 | -62,073 | 1,590,118 | -4% | -$434,511 | ||||||
2025-11-03 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $5.64 | -22,000 | 1,210,391 | -2% | -$124,047 | ||||||
2025-10-30 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $31.44 | -6,515 | 121,713 | -5% | -$204,860 | ||||||
2025-10-30 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $31.44 | -17,606 | 268,674 | -6% | -$553,608 | ||||||
2025-10-30 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $31.44 | -6,920 | 143,271 | -5% | -$217,595 | ||||||
| D | 2025-10-30 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $31.44 | -31,379 | 738,809 | -4% | -$986,691 | |||||
2025-10-30 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $31.44 | -5,517 | 111,008 | -5% | -$173,478 | ||||||
2025-10-30 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $31.44 | -1,016 | 51,030 | -2% | -$31,947 | ||||||
| M | 2025-10-28 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $25.90 | -400,408 | 779,652 | -34% | -$10,368,938 | |||||
2025-10-28 | CGEM | Cullinan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $8.40 | +165,667 | 8,963,500 | +2% | +$1,391,686 | ||||||
| M | 2025-10-28 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.50 | -24,553 | 14,573,983 | 0% | -$159,655 | |||||
| M | 2025-10-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $7.40 | -40,529 | 337,469 | -11% | -$299,949 | |||||
2025-10-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $7.29 | -21,664 | 313,631 | -6% | -$157,931 | ||||||
2025-10-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $7.29 | -30,897 | 521,823 | -6% | -$225,239 | ||||||
2025-10-27 | NMRA | Neumora Therapeutics, Inc. | Burow Kristina | Dir, 10% | P - Purchase | $2.61 | +1,915,700 | 33,895,555 | +6% | +$4,999,977 | ||||||
2025-10-27 | NMRA | Neumora Therapeutics, Inc. | Arch Venture Partners Xii, LLC | 10% | P - Purchase | $2.61 | +1,915,700 | 33,847,838 | +6% | +$4,999,977 | ||||||
2025-10-27 | NMRA | Neumora Therapeutics, Inc. | Arch Venture Partners X, LLC | 10% | P - Purchase | $2.61 | +1,915,700 | 33,847,838 | +6% | +$4,999,977 | ||||||
| D | 2025-10-29 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $60.99 | -30,000 | 660,482 | -4% | -$1,829,737 | |||||
2025-10-29 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | SVP, Finance | S - Sale | $6.35 | -896 | 85,662 | -1% | -$5,690 | ||||||
2025-10-29 | AURA | Aura Biosciences, Inc. | De Los Pinos Elisabet | See Remarks | S - Sale | $6.35 | -9,049 | 602,154 | -1% | -$57,461 | ||||||
2025-10-28 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $119.39 | -10,000 | 581,203 | -2% | -$1,193,926 | ||||||
2025-10-27 | BEAM | Beam Therapeutics Inc. | Fmr LLC | See Remark 1, 10% | S - Sale | $26.68 | -459 | 1,980,688 | 0% | -$12,246 | ||||||
| M | 2025-10-24 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.01 | -113,099 | 14,598,536 | -1% | -$679,870 | |||||
| M | 2025-10-23 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $28.06 | -221,166 | 1,180,060 | -16% | -$6,204,863 | |||||
2025-10-23 | XFOR | X4 Pharmaceuticals, Inc | Craig Adam R | Exec COB | P - Purchase | $2.90 | +86,206 | 376,087 | +30% | +$249,997 | ||||||
| D | 2025-10-24 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $12.00 | -2,678 | 3,594 | -43% | -$32,136 | |||||
2025-10-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $30.88 | -2,240 | 206,495 | -1% | -$69,160 | ||||||
| D | 2025-10-24 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $16.00 | -21,000 | 3,744,233 | -1% | -$336,000 | |||||
| D | 2025-10-23 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $5.70 | -100,000 | 954,229 | -9% | -$570,000 | |||||
2025-10-22 | IMVT | Immunovant, Inc. | Geffner Michael | Chief Medical Officer | S - Sale | $19.03 | -2,595 | 217,958 | -1% | -$49,383 | ||||||
2025-10-22 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $19.03 | -2,520 | 200,814 | -1% | -$47,956 | ||||||
| M | 2025-10-22 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.07 | -298,649 | 14,711,635 | -2% | -$1,812,378 | |||||
2025-10-21 | ALLO | Allogene Therapeutics, Inc. | Parker Geoffrey M. | CFO | S - Sale | $1.26 | -36,744 | 1,276,796 | -3% | -$46,169 | ||||||
| M | 2025-10-20 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $29.34 | -117,050 | 1,401,226 | -8% | -$3,433,992 | |||||
| M | 2025-10-20 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.23 | -330,210 | 15,010,284 | -2% | -$2,058,247 | |||||
2025-10-21 | MGTX | Meiragtx Holdings Plc | Giroux Richard | CFO, COO | S - Sale | $8.87 | -24,000 | 919,646 | -3% | -$212,880 | ||||||
| M | 2025-10-14 | CGEM | Cullinan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $8.46 | +248,749 | 17,361,949 | +1% | +$2,103,912 | |||||
| M | 2025-10-17 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $30.19 | -37,533 | 1,166,909 | -3% | -$1,133,103 | |||||
| D | 2025-10-17 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $13.65 | -1,312 | 6,738 | -16% | -$17,907 | |||||
| D | 2025-10-20 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Chief Medical Officer | S - Sale+OE | $5.96 | -2,895 | 33,819 | -8% | -$17,254 | |||||
| D | 2025-10-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $10.17 | -1,635 | 5,188 | -24% | -$16,628 | |||||
| D | 2025-10-17 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $67.91 | -50,895 | 339,863 | -13% | -$3,456,279 | |||||
2025-10-17 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | Pres, CEO | S - Sale | $6.00 | -25,500 | 356,721 | -7% | -$153,000 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | See Tai Sandi | Chief Development Officer | S - Sale | $8.94 | -3,888 | 65,862 | -6% | -$34,767 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | Robertson Jenny | GC | S - Sale | $8.94 | -3,526 | 68,930 | -5% | -$31,530 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Chief Technical Officer | S - Sale | $8.94 | -2,115 | 64,197 | -3% | -$18,913 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | Adler Eric | Chief Medical Officer | S - Sale | $8.94 | -3,382 | 73,261 | -4% | -$30,242 | ||||||
2025-10-17 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $8.94 | -13,133 | 242,118 | -5% | -$117,436 | ||||||
| M | 2025-10-15 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $31.88 | -73,676 | 1,204,442 | -6% | -$2,348,744 | |||||
| M | 2025-10-15 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $29.54 | -464,025 | 15,104 | -97% | -$13,707,361 | |||||
| M | 2025-10-15 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.08 | -29,515 | 15,340,494 | 0% | -$179,563 | |||||
2025-10-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $118.08 | -2,500 | 157,055 | -2% | -$295,200 | ||||||
2025-10-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $118.08 | -3,000 | 110,193 | -3% | -$354,240 | ||||||
2025-10-16 | AURA | Aura Biosciences, Inc. | Plavsic Mark | CTO | S - Sale | $6.35 | -12,169 | 197,287 | -6% | -$77,273 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | P - Purchase | $0.80 | +17,000 | 71,832 | +31% | +$13,607 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Chow Gregory K. | CFO | P - Purchase | $0.81 | +19,750 | 19,750 | New | +$15,998 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Chung Jane | CEO | P - Purchase | $0.80 | +12,500 | 122,850 | +11% | +$10,011 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Matsui Connie | Dir | P - Purchase | $0.80 | +50,000 | 50,000 | New | +$39,950 | ||||||
2025-10-15 | STRO | Sutro Biopharma, Inc. | Pauling David | Chief Admin. Ofcr., GC | P - Purchase | $0.80 | +12,504 | 71,737 | +21% | +$9,993 | ||||||
2025-10-15 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $91.04 | -5,364 | 8,466 | -39% | -$488,315 | ||||||
| M | 2025-10-10 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $31.08 | -96,657 | 1,278,118 | -7% | -$3,003,706 | |||||
| D | 2025-10-14 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $66.60 | -4,242 | 290,758 | -1% | -$282,517 | |||||
| D | 2025-10-14 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $66.60 | -1,076 | 83,402 | -1% | -$71,662 | |||||
| D | 2025-10-15 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Chief Medical Officer | S - Sale+OE | $61.42 | -59,576 | 109,992 | -35% | -$3,659,254 | |||||
| D | 2025-10-13 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $48.54 | -25,000 | 284,047 | -8% | -$1,213,540 | |||||
| D | 2025-10-13 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $43.25 | -1,000 | 0 | -100% | -$43,250 | |||||
2025-10-10 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $12.05 | +1,659 | 575,095 | 0% | +$19,991 | ||||||
| D | 2025-10-13 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Chief Medical Officer | S - Sale+OE | $60.00 | -3,114 | 118,359 | -3% | -$186,840 | |||||
| M | 2025-10-09 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.14 | -251,360 | 15,370,009 | -2% | -$1,543,899 | |||||
| D | 2025-10-10 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $9.24 | -1,775 | 57,079 | -3% | -$16,401 | |||||
2025-10-09 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale | $10.00 | -2,408 | 5,188 | -32% | -$24,080 | ||||||
| D | 2025-10-13 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $59.19 | -5,000 | 0 | -100% | -$295,949 | |||||
| M | 2025-10-08 | CGEM | Cullinan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $6.73 | +1,459,641 | 16,194,827 | +10% | +$9,826,941 | |||||
2025-10-09 | RGNX | Regenxbio Inc. | Simpson Curran | CEO | S - Sale | $12.62 | -20,811 | 216,162 | -9% | -$262,635 | ||||||
| D | 2025-10-10 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $6.04 | -100,000 | 954,229 | -9% | -$604,000 | |||||
| M | 2025-10-08 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $33.16 | -124,146 | 1,374,775 | -8% | -$4,116,369 | |||||
| D | 2025-10-09 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $43.99 | -5,903 | 0 | -100% | -$259,673 | |||||
| M | 2025-10-08 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $31.96 | -5,517 | 91,525 | -6% | -$176,315 | |||||
2025-10-08 | IMVT | Immunovant, Inc. | Geffner Michael | Chief Medical Officer | S - Sale | $16.30 | -1,272 | 220,553 | -1% | -$20,734 | ||||||
2025-10-08 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $16.30 | -1,585 | 203,334 | -1% | -$25,836 | ||||||
| M | 2025-10-08 | ATYR | Atyr Pharma Inc | Schimmel Paul | Dir | P - Purchase | $0.91 | +1,000,000 | 2,101,056 | +91% | +$911,801 | |||||
| M | 2025-10-07 | FENC | Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LP | 10% | S - Sale | $9.48 | -67,114 | 4,010,100 | -2% | -$636,229 | |||||
2025-10-07 | INBX | Inhibrx Biosciences, Inc. | Viking Global Investors LP | 10% | S - Sale | $32.25 | -350,000 | 102,864 | -77% | -$11,287,500 | ||||||
| M | 2025-10-07 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $5.99 | -538,375 | 15,621,369 | -3% | -$3,223,939 | |||||
2025-10-08 | ZIVO | Zivo Bioscience, Inc. | Maggiore Christopher D. | Dir, 10% | P - Purchase | $12.01 | +23,682 | 517,526 | +5% | +$284,421 | ||||||
| M | 2025-10-06 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $36.12 | -98,387 | 1,498,921 | -6% | -$3,553,499 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |